share_log

Goldman Sachs Downgrades Veracyte to Neutral, Lowers Price Target to $37

Goldman Sachs Downgrades Veracyte to Neutral, Lowers Price Target to $37

高盛将veracyte股票评级调降至中立,将目标价格下调至37美元
Benzinga ·  12/05 03:53  · 评级/大行评级

Goldman Sachs analyst Matthew Sykes downgrades Veracyte (NASDAQ:VCYT) from Buy to Neutral and lowers the price target from $38 to $37.

高盛分析师Matthew Sykes将veracyte(纳斯达克:VCYT)的评级从买入下调至中立,并将目标价格从38美元下调至37美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发